C. Michael Gibson/LinkedIn
Nov 8, 2025, 11:18
C. Michael Gibson and Atul Verma on OCEAN Trial: Rivaroxaban VS Aspirin in AF
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Atul Verma and I discuss the OCEAN trial: In AF patients after successful catheter ablation, is long-term anticoagulation with low-dose rivaroxaban more effective than aspirin in preventing stroke or systemic embolism?
AHA25 View it here.”
Stay updated with Hemostasis Today.
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities
-
Feb 22, 2026, 09:12Arun V JÖ‰ The Hidden Risks in Every Blood Bag
-
Feb 22, 2026, 08:56Parandzem KhachatryanÖ‰ How Hard Is It to Be a Mom, a Wife, a Professor, and a Doctor All at Once?
-
Feb 22, 2026, 08:46Anirban Sen Gupta Presents Bioinspired Platelet Surrogates at MTEC
-
Feb 22, 2026, 08:31Heghine Khachatryan: Advancing Care for Women and Girls with Bleeding Disorders is A Matter of Equity